GHRP-6
A synthetic growth hormone secretagogue known for potent GH release and significant appetite stimulation through ghrelin receptor activation.
What is GHRP-6?
GHRP-6 is one of the earliest synthetic growth hormone releasing peptides developed. It acts on the ghrelin receptor to stimulate growth hormone release from the pituitary gland. It is notable for its strong appetite-stimulating effects, which can be beneficial for those needing to increase caloric intake but may be undesirable for others.
What GHRP-6 Is Investigated For
GHRP-6 is investigated for growth hormone release, appetite stimulation, gastric motility, and body composition, with its most distinctive pharmacological feature being pronounced ghrelin-receptor-mediated hunger induction. The strongest evidence is for the appetite effect itself — well-characterized acute hunger within 15–60 minutes of injection, making GHRP-6 the preferred GHRP specifically for cachexia, wasting, and medication-induced appetite suppression contexts where stimulating caloric intake is the therapeutic goal. Its GH-releasing effect is moderate and less potent than GHRP-2 or hexarelin, and it elevates cortisol and prolactin more than either, making it a poor first-line choice for body-composition goals. The honest caveats are that GHRP-6 is not FDA-approved for any indication, long-term human safety data outside diagnostic testing is essentially absent, and it is prohibited under WADA S2 at all times with routine LC-MS/MS urinary detection. As the foundational first-generation GHRP from the Bowers-Momany program at Tulane, GHRP-6's historical importance is enormous, but modern compound selection generally favors GHRP-2 or ipamorelin for GH goals — reserving GHRP-6 for the specific appetite-stimulation use case.
History & Discovery
GHRP-6 is the foundational first-generation synthetic growth hormone-releasing peptide, emerging from the sustained medicinal-chemistry collaboration between Frank Momany and Cyril Bowers at Tulane University during the 1980s. Their work began from the observation that a met-enkephalin analog could release GH in pituitary cell cultures, and they iterated through a series of short synthetic peptides that retained GH-releasing potency while stripping away opioid activity. The hexapeptide sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 emerged as the first consistently active compound, first described in the peer-reviewed literature in the early 1980s and formalized as GHRP-6 in subsequent work. Its discovery predated the identification of the underlying receptor: the GHS-R1a receptor was not cloned until 1996, and its endogenous ligand ghrelin was not identified until 1999, meaning GHRP-6 spent more than a decade as a pharmacologically orphan compound whose mechanism was evident only in retrospect. GHRP-6 was explored in early human trials for GH-deficient children and as a diagnostic tool, but it was never approved as a therapeutic drug in any major market. Its historical importance is as the reference first-generation GHRP — the compound against which all subsequent GHRPs (GHRP-2, hexarelin, ipamorelin) were benchmarked. The two features that most shaped its later clinical identity were pronounced appetite stimulation (a ghrelin-receptor-mediated effect that tracks the discovery of ghrelin as the endogenous hunger hormone) and meaningful cortisol and prolactin elevation at clinical doses. GHRP-6 migrated into the research-chemical and compounding-pharmacy market during the 2000s, and today is most commonly chosen specifically for the appetite-stimulation use case — cachexia, wasting, medication-induced appetite suppression — where the feature is the point rather than an unwanted side effect.
How It Works
GHRP-6 mimics the hunger hormone ghrelin, telling your brain to release growth hormone and increase appetite. It creates a strong growth hormone pulse but also significantly increases the desire to eat.
GHRP-6 is a potent agonist of the GHS-R1a receptor with additional effects on cortisol and prolactin release through ACTH stimulation. It triggers GH release through IP3/DAG-mediated calcium signaling in pituitary somatotrophs. Its strong ghrelin-mimetic activity in the hypothalamus drives appetite stimulation through NPY/AgRP neuron activation.
Evidence Snapshot
Human Clinical Evidence
Moderate. Well-studied for GH release kinetics. Used in diagnostic testing. Several clinical studies on appetite and GH secretion.
Animal / Preclinical
Extensive. One of the most studied GHRPs in preclinical models.
Mechanistic Rationale
Strong. GHS-R1a pharmacology is well-characterized.
Research Gaps & Open Questions
What the current literature has not yet settled about GHRP-6:
- 01Long-term (>12 month) human safety data outside diagnostic-test populations is essentially absent.
- 02Whether GHRP-6's cortisol and prolactin elevation at chronic wellness-range doses produces clinically meaningful HPA-axis or reproductive-endocrine consequences over months has not been characterized.
- 03The magnitude and durability of the appetite-stimulation effect in human wasting and cachexia populations has not been quantified in modern placebo-controlled trials, even though this is the use case most frequently cited for GHRP-6 specifically.
- 04Head-to-head comparisons between GHRP-6 and GHRP-2 or ipamorelin on long-duration body-composition and functional endpoints in non-deficient adults are absent.
- 05Whether GHRP-6's renal-protective, cardiac, and pulmonary preclinical signals translate to any human clinical outcome has not been tested.
- 06Optimal dosing design for the appetite-specific use case — dose, timing relative to meals, stacking vs. monotherapy — has not been standardized in published clinical literature.
Forms & Administration
GHRP-6 is administered via subcutaneous injection, typically 2-3 times daily on an empty stomach. It is often combined with a GHRH analog. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Protocols commonly discussed for GHRP-6 run 100–200 mcg per dose, most frequently 100 mcg per injection two to three times daily. The dose-response curve flattens above roughly 200 mcg per dose; higher single doses do not produce proportionally greater GH release and do disproportionately elevate cortisol, prolactin, and ACTH. When GHRP-6 is chosen specifically for appetite stimulation in wasting or cachexia contexts, the pre-meal 100 mcg dose is the most common configuration because the appetite effect is acute and ghrelin-receptor-mediated.
Frequency
GHRP-6 is short-acting (plasma half-life roughly 15–60 minutes), so dosing is typically split across two to three discrete pulses per day — commonly morning, pre-meal or midday, and bedtime. When the appetite effect is the therapeutic goal, timing 15–30 minutes before a target meal aligns the ghrelin-receptor activation with the intended feeding window. When GH release is the primary goal, timing on an empty stomach matters more than meal-alignment. The standard dual-pathway stacking rationale with a GHRH analog applies to GHRP-6 as it does to the other GHRPs: GHRP-6 acts at the ghrelin/GHS-R1a receptor, the GHRH analog at the GHRH receptor, and the two together produce a larger synergistic GH pulse than either alone.
Timing Considerations
Time of day
Bedtime is the most common window, aligned with the natural nocturnal GH pulse; multi-dose protocols typically add a mid-morning fasted dose and a pre-workout dose.
Relative to meals
Fasted — at least 30 minutes before food and 2+ hours after a meal. Elevated insulin and circulating amino acids substantially blunt GH release, so meal timing directly affects pulse amplitude.
Relative to exercise
Independent of training, though some users add a pre-workout dose on training days for an additional GH pulse around exercise. Expect meaningful appetite stimulation in the 30–60 min window after injection, which may or may not be desirable depending on your goal.
Cycle Length
Commonly discussed protocols run 8–12 weeks on followed by a 4-week break. Pituitary desensitization with chronic ghrelin-receptor stimulation is a theoretical concern, though GHRP-6 appears less prone to tachyphylaxis than hexarelin. No long-duration human trial has directly compared continuous versus cycled GHRP-6 dosing. In cachexia and wasting use cases, continuous use during active illness is more commonly discussed than in wellness use.
Protocol Notes
GHRP-6 is supplied as a lyophilized powder, typically 5 mg or 10 mg per vial, reconstituted in bacteriostatic water. A 5 mg vial in 2 mL of BAC water yields 2,500 mcg/mL, making 100 mcg roughly 0.04 mL or 4 units on an insulin syringe. Subcutaneous injection into the abdominal fat pad is the standard route. Because GHRP-6 acts through the ghrelin receptor, the interaction with eating is central to dosing design. For GH-release goals, injection at least 30 minutes before eating or 2+ hours after a meal is standard, because circulating amino acids and elevated insulin blunt GH release. For appetite-stimulation goals, injection 15–30 minutes before a target meal leverages the acute hunger effect. Bedtime dosing is often avoided in users for whom the appetite stimulation is unwanted, since it can drive nighttime eating. When stacked with CJC-1295 no-DAC or sermorelin, both peptides are typically drawn into the same syringe and injected together.
GHRP-6 is not FDA-approved for any indication. The numbers above describe commonly-referenced protocols, not a prescription. Use should be supervised by a qualified clinician with appropriate IGF-1, glucose, cortisol, and prolactin monitoring given GHRP-6's off-target hormonal effects.
Timeline of Effects
Onset
Appetite stimulation is the first and most distinctive GHRP-6 signal — pronounced hunger typically appears within 15–60 minutes of injection, tracking the acute ghrelin-receptor activation. Sleep-depth changes and subjective recovery improvement follow the general GHRP pattern, typically within 1–2 weeks of consistent daily dosing. The acute GH pulse is immediate (peak within 15–30 minutes of injection), but downstream IGF-1 elevation requires several days of repeat dosing to accumulate meaningfully in serum.
Peak Effect
Serum IGF-1 typically rises progressively over the first 3–6 weeks of consistent dosing and plateaus. The magnitude of IGF-1 elevation achievable with GHRP-6 at typical wellness doses is modestly lower than with GHRP-2 or hexarelin at comparable dosing; its strongest acute effect remains appetite rather than GH release per se. Body-composition changes in wasting and cachexia populations — where the appetite effect drives meaningful caloric intake gains — can become visible within weeks, because the primary mechanism is behavioral (increased eating) as much as it is endocrine.
After Discontinuation
Because GHRP-6 does not suppress endogenous GHRH or ghrelin production, endogenous pulsatile GH secretion returns to baseline within days of stopping dosing. Appetite normalizes within hours of the last dose. IGF-1 drifts back to pre-treatment levels over 2–4 weeks. Cortisol and prolactin elevations, to the extent they were present, normalize quickly. No post-cycle therapy is required — GHRP-6 does not suppress the HPG axis. Weight gained during the on-cycle specifically from ghrelin-driven appetite stimulation may persist or regress depending on whether underlying caloric intake is sustained.
Monitoring & Measurement
Bloodwork & Labs
- •IGF-1 (serum) — the practical response marker; expect 20–40% rises at typical doses
- •Fasting glucose and HbA1c
- •Prolactin and cortisol — GHRP-6 is non-selective, so modest rises are expected; track to distinguish tolerable from problematic
- •Lipid panel
Functional & Performance Tests
- •DEXA scan for lean mass
- •Waist circumference
- •Daily appetite and hunger rating — GHRP-6's most distinctive effect is strongly orexigenic, and that's the feature that determines whether it suits your goal
When to Test
Baseline, 6 weeks, and 12 weeks.
Interpretation & Notes
GHRP-6's defining characteristic is non-selectivity — unlike ipamorelin, you should expect modest rises in prolactin and cortisol as part of normal pharmacology. A doubling of either warrants dose reduction, or switching to ipamorelin if the goal is GH pulse without adjacent-hormone effects. The appetite-stimulating effect is the practical differentiator: useful if your goal is mass gain during a caloric surplus, actively counterproductive during a cut. Track appetite deliberately — it's the signal that usually determines whether to continue or switch. IGF-1 response is similar in magnitude to other GHRPs (20–40%). Panels via LabCorp, Quest, Marek Health, Ulta Lab Tests.
Common Questions
Who GHRP-6 Is NOT For
- •Active or recent-history cancer — GH and IGF-1 elevation may accelerate proliferation of existing malignancies; clinicians universally exclude active cancer from GH-secretagogue protocols. The cachexia-and-appetite use case is the notable exception, where oncology teams may consider ghrelin-receptor agonism with careful weighing of tumor biology, but this falls well outside wellness use.
- •Pregnancy — no human pregnancy safety data; reproductive-toxicology characterization is absent, and combined GH, cortisol, and appetite effects have not been studied in pregnancy.
- •Breastfeeding — no data on transfer into breast milk or effects on nursing infants.
- •Diabetes or uncontrolled insulin resistance — GH opposes insulin action, and GHRP-6's cortisol elevation further antagonizes glycemic control. The additional appetite stimulation compounds the metabolic concern in patients for whom caloric intake is already a therapeutic target.
- •Eating disorders or contexts where appetite stimulation is clinically inappropriate — GHRP-6's acute and pronounced hunger effect is a feature in cachexia and wasting but a meaningful risk in patients with binge-eating disorder, uncontrolled obesity, or other conditions in which driving increased caloric intake is harmful.
- •Active hypercortisolism, Cushing's disease, or poorly controlled HPA-axis disorders — GHRP-6 stimulates ACTH and cortisol release, and can exacerbate HPA-axis pathology.
- •Active acromegaly or pituitary adenoma — further stimulation of GH-producing cells is contraindicated.
- •Pediatric use outside a diagnosed GH deficiency under specialist supervision — development-related signaling effects from unmonitored secretagogue use are a concern.
Drug & Supplement Interactions
Documented clinical drug interactions for GHRP-6 are sparse; the relevant concerns track GHRP-class pharmacology with particular emphasis on the appetite and cortisol effects unique to this compound. Glucose-regulating medications — insulin, sulfonylureas, GLP-1 receptor agonists — interact with GH's counter-regulatory effect on glucose and with GHRP-6's added cortisol elevation and appetite stimulation. The combination can substantially destabilize glycemic control, and the appetite-driven behavioral component is not captured by standard drug-interaction frameworks. Patients on weight-management pharmacotherapy, including GLP-1 agonists for obesity, are a particular concern because GHRP-6's hunger effect directly antagonizes the therapeutic goal. Corticosteroids (prednisone, dexamethasone) interact in a dual way: acute glucocorticoid administration can enhance GH response to GHRP-6, while chronic glucocorticoid exposure suppresses spontaneous GH and blunts cumulative IGF-1 gains. Somatostatin analogs (octreotide, lanreotide) directly oppose GH release and will pharmacologically antagonize GHRP-6. Dopamine agonists may be relevant where GHRP-6's prolactin elevation becomes clinically meaningful. Thyroid hormone status matters for GH response. Patients on any regular medication should disclose GHRP-6 use to their prescribing clinician.
Safety Profile
Common Side Effects
Cautions
- • Strong appetite stimulation may be problematic
- • Elevates cortisol more than other GHRPs
- • Not FDA-approved
- • Monitor blood sugar levels
What We Don't Know
Long-term metabolic effects of chronic ghrelin receptor activation are not fully understood.
Legal Status
United States
GHRP-6 is not FDA-approved for any medical indication. It has historically been available through state-licensed compounding pharmacies under individualized prescription, though the FDA's ongoing 503A bulk-list review has challenged the compounding status of GH secretagogues generally, including GHRP-6. It is widely sold in the research-chemical market labeled 'not for human consumption,' which is not an authorized channel for human use. Regulatory posture is actively evolving.
International
The European Medicines Agency and UK MHRA have not authorized GHRP-6 as a medicine. Australia's TGA classifies GH secretagogues as Schedule 4 prescription-only substances. Canada treats it as an unapproved investigational agent. Unlike GHRP-2, GHRP-6 has not received regulatory approval in any major market even for diagnostic use.
Sports & Competition
GHRP-6 is explicitly prohibited under WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics), which covers GH secretagogues and ghrelin-receptor agonists — prohibited at all times, both in and out of competition. LC-MS/MS urinary detection methods for GHRP-6 and its metabolites are well-established and used routinely in WADA-accredited laboratories. Athletes subject to WADA, USADA, UKAD, or equivalent bodies must avoid it.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
GHRP-6's appetite stimulation is a side effect and not a real use case.
Reality
Appetite stimulation is one of the most pharmacologically distinctive features of GHRP-6 and is exactly what has driven its continued clinical interest in wasting, cachexia, and medication-induced appetite suppression. For those populations it is the feature, not the bug. The feature/side-effect framing depends entirely on the patient and the goal — a body-composition-focused user and a cachectic oncology patient experience the same pharmacology differently.
Myth
GHRP-6 is a weaker version of GHRP-2 or hexarelin — always pick the newer compound.
Reality
GHRP-6 does produce a smaller GH pulse at comparable doses than GHRP-2 or hexarelin, but 'weaker' is not the same as 'worse.' Its particular pharmacology — strong ghrelin-receptor appetite effect, moderate GH-releasing effect, well-characterized safety profile from decades of study — makes it the most appropriate GHRP for some use cases (appetite stimulation) and unnecessary for others (maximal IGF-1 elevation). Evaluating GHRPs on a single 'potency' axis misses the mechanistic differences that should drive compound selection.
Myth
GHRP-6 is FDA-approved because it has been around since the 1980s.
Reality
Duration of research interest is not the same as regulatory approval. GHRP-6 has been studied for more than 40 years without achieving approval in any major market. Its availability in the US has been through compounding-pharmacy and research-chemical channels only, and that access is narrowing.
Myth
The appetite stimulation wears off with continued use, so it's not a problem for body-composition users.
Reality
Published human studies and consistent user reports indicate the acute appetite effect does not fully tolerize with continued GHRP-6 use at standard doses; cycles of weeks to months commonly retain the hunger response, particularly in pre-meal dosing windows. Users pursuing fat loss with GHRP-6 frequently find the appetite effect persistently problematic, which is a meaningful reason to consider GHRP-2 or ipamorelin instead.
Myth
GHRP-6 is undetectable in drug testing because it is a short peptide and clears quickly.
Reality
LC-MS/MS urinary detection methods for GHRP-6 and its metabolites are well-validated and routinely used in WADA-accredited labs. Short plasma half-life does not equal undetectability — metabolites are excreted in urine and remain measurable for a window after dosing.
Published Research
34 studiesGrowth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation
Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis
Growth hormone-releasing peptide 6 (GHRP-6) hydrogel for acute kidney injury therapy via metabolic regulation.
Growth hormone releasing peptide-6 (GHRP-6) prevents doxorubicin-induced myocardial and extra-myocardial damages by activating prosurvival mechanisms.
[D-Lys3]-GHRP-6 exhibits pro-autophagic effects on skeletal muscle.
Role of epidermal growth factor and growth hormone-releasing peptide-6 in acceleration of renal tissue repair after kanamycin overdosing in rats
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers
Effects of ghrelin, GH-releasing peptide-6 (GHRP-6) and GHRH on GH, ACTH and cortisol release in hyperthyroidism before and after treatment
Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus
Diagnosis of adrenal insufficiency using the GHRP-6 Test: comparison with the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease
Adrenocorticotrophic hormone (ACTH) responsiveness to ghrelin increases after 6 months of ketoconazole use in patients with Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6)
Ghrelin and GHRP-6-induced ACTH and cortisol release in thyrotoxicosis
Association between tumoral GH-releasing peptide receptor type 1a mRNA expression and in vivo response to GH-releasing peptide-6 in ACTH-dependent Cushing's syndrome patients
Decreased ghrelin-induced GH release in thyrotoxicosis: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH
Decreased GH secretion and enhanced ACTH and cortisol release after ghrelin administration in Cushing's disease: comparison with GH-releasing peptide-6 (GHRP-6) and GHRH
Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers
Growth hormone response to GHRH + GHRP-6 in type 2 diabetes during euglycemic and hyperglycemic clamp
GHRP-6 is able to stimulate cortisol and ACTH release in patients with Cushing's disease: comparison with DDAVP
Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism
Effects of fasting and pegvisomant on the GH-releasing hormone and GH-releasing peptide-6 stimulated growth hormone secretion
Acute dexamethasone administration enhances GH responsiveness to GH releasing peptide-6 (GHRP-6) in man
Growth hormone (GH) response to GH-releasing peptide-6 and GH-releasing hormone in normal-weight and overweight patients with non-insulin-dependent diabetes mellitus
Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans
Growth hormone (GH)-releasing peptide-6 requires endogenous hypothalamic GH-releasing hormone for maximal GH stimulation
Different effects of growth hormone releasing peptide (GHRP-6) and GH-releasing hormone on GH release in endogenous and exogenous hypercortisolism
Growth hormone responses to GH-releasing peptide (GHRP-6) in hypothyroidism
Influence of endogenous cholinergic tone and growth hormone-releasing peptide-6 on exercise induced growth hormone release
Growth hormone releasing hexapeptide-6 (GHRP-6) test in the diagnosis of GH-deficiency.
Evaluation of pituitary GH reserve with GHRP-6.
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients
Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood
Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man
The effect of an opiate antagonist on the hormonal changes induced by hexarelin
Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess
Quick Facts
- Class
- Growth Hormone Secretagogue
- Tier
- C
- Evidence
- Moderate
- Safety
- Moderate Data
- Updated
- May 2026
- Citations
- 34PubMed
Also known as
Tags
Peptide Families
Related Goals
Conditions Discussed
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.